News

Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial
Praxis Precision Medicines’ oral vormatrigine stopped 100% of seizures in 22% of patients in a Phase II trial. The RADIANT ...
Eisai stock rises after strong Leqembi sales boost quarterly results
Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...
McKnight's Long-Term Care News10h
Two Alzheimer’s drugs show long-term promise in slowing disease progression
New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...
European Medical Journal6h
The Epilepsy Deaths Register: Third-Party Reports of Sudden Unexpected Death in Epilepsy in Adults and Older Adolescents
Sudden unexpected death in epilepsy (SUDEP) is the most significant complication of epilepsy, with an incidence of 1.2 per ...
European Medical Journal6h
The Intersection of Menopause and Epilepsy: A Review of Current Knowledge and Gaps
Epilepsy is a serious and common neurological condition, characterised by recurring, unprovoked seizures, affecting ...